AGP Picks
View all

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

Press releases published on July 28, 2026

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
Cato Healthcare Supply Strengthens Executive Leadership Team
Grief goes global on screen as first-of-its-kind festival receives over 500 films from six continents
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy
CorVascular Named Exclusive U.S. Importer and Vascular Distributor for ASUS FDA-Cleared Ultrasound Portfolio
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
Slate Medicines Establishes Clinical and Scientific Advisory Boards to Advance Next-Generation Migraine Prevention Therapeutics
New Survey: Digestive Side Effects Cause 41% of GLP-1 Users to Suffer in Silence, Self-Adjust, or Consider Quitting
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin
Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Times of Rhode Island

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.